SCHEDULE: Farallon Capital Discloses 9.8% Stake in Tango Therapeutics

Farallon Capital Management and affiliated entities have reported beneficial ownership of 9.8% of Tango Therapeutics' common stock, primarily through warrants and shares.

Summary

• Farallon Capital Management, L.L.C. and related entities (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of Tango Therapeutics, Inc. common stock.
• The Reporting Persons collectively hold 16,270,187 shares, representing 9.8% of the class of securities.
• This ownership comprises 12,277,000 shares and 3,993,187 shares underlying exercisable warrants.
• The filing specifies that the "Farallon Funds" hold these securities, with Farallon Capital Management, L.L.C. acting as the investment manager.
• The filing is an amendment (Amendment No. 5) and the event date requiring the filing is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake. The focus is on disclosure rather than strategic shifts.

Positives

• Significant investment by a major asset manager (Farallon Capital) suggests confidence in Tango Therapeutics' long-term prospects.
• The disclosure clearly outlines the beneficial ownership, providing transparency to the market.
• The ownership stake of 9.8% is substantial, indicating a strong interest in the company's performance.

Negatives

• The filing does not contain any negative financial results or operational updates, as it is a disclosure of ownership.
• No specific details are provided regarding the strategy behind this investment or any expected changes.

Risks

• The exercise of warrants is subject to a Beneficial Ownership Limitation of 9.99%, which could affect future ownership levels if the company issues more shares.
• The concentration of ownership by a single entity could lead to potential influence on corporate decisions, though the filing states the shares were not acquired for changing or influencing control.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific future guidance from the company.

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Farallon Capital are common in the biotechnology sector, often reflecting strategic investments in companies with promising drug pipelines or development stages.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings, potentially influencing market perception.
• Management: Awareness of a substantial shareholder with a vested interest in the company's performance.

Next Steps

• Continued monitoring of Farallon Capital's stake and any potential future filings or disclosures related to their investment in Tango Therapeutics.

Key Dates

Keywords

Tango Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Warrants, Investment Management, Shareholder Disclosure